Gum Tech (GUMM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gum Tech (GUMM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: john michael winesette who wrote (110)	1/31/1999 11:30:00 AM
From: DanZ	Read Replies (1) of 133

John, I think your question will be answered at exchange2000.com. The focus of most researchers looking for a cure for the common cold has centered on blocking the rhinovirus from attaching itself to the ICAM-1 receptor. I think this adds credence to the science behind Zicam because many reputable researchers, doctors, and scientists have published papers on this topic. GumTech is the first to market with a product based on these principles, and therefore, has a lead over competitors that may develop products. I also think this increases the likelihood that a health care company such as Johnson & Johnson or American Home Prouducts would be interested in buying the Zicam brand name instead of developing their own remedy. Quite obviously this depends on the market acceptance for Zicam, how well it works, and the cost to develop a new product versus the cost to buy Zicam. Still, I have a feeling that Gel Tech now has the attention of some big companies since Zicam is already on the shelves at everyday stores like Albertsons and Eckerds. Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next